HLA-DR expression in conjunctival cells after latanoprost

Area of Science:

• Ophthalmology
• Immunology
• Cell Biology

Background:

• Ocular hypertension and primary open-angle glaucoma are common conditions.
• Latanoprost is a widely used prostaglandin analog for lowering intraocular pressure.
• The ocular surface effects of latanoprost, particularly regarding inflammation, require further investigation.

Purpose of the Study:

• To evaluate the impact of latanoprost 0.005% on the ocular surface in patients with ocular hypertension or primary open-angle glaucoma.
• To assess clinical signs, intraocular pressure, corneal sensitivity, and conjunctival cytology.
• To investigate the expression of Human Leukocyte Antigen - antigen D Related (HLA-DR) as a marker of ocular surface inflammation.

Main Methods:

• Randomized, controlled, masked study involving 14 patients treated with latanoprost 0.005% or artificial tears for 4 months.
• Regular clinical assessments including intraocular pressure, corneal sensitivity (Cochet-Bonnet test), and fluorescein staining.
• Conjunctival impression and brush cytology combined with immunohistochemical techniques to detect HLA-DR expression.

Main Results:

• No significant differences were observed in symptoms, intraocular pressure, corneal sensitivity, or fluorescein staining between the groups.
• A statistically significant increase in HLA-DR expression was found in the conjunctival cells of patients treated with latanoprost (p < 0.001).
• HLA-DR is a known marker for ocular surface inflammation.

Conclusions:

• Latanoprost therapy may induce a subclinical inflammatory response on the ocular surface.
• The elevated HLA-DR expression suggests an inflammatory reaction in patients using latanoprost.
• The precise mechanism driving this latanoprost-induced inflammation remains undetermined.